The purpose of this toolkit is to assist TB programs in developing and implementing a TB eDOT program. Because eDOT programs can be very diverse to accommodate individual TB program needs, this toolkit provides general information that can be tailored to fit program needs.
The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.
This online course is designed to provide TB control staff, clinicians, and nurses a brief overview of basic principles of molecular technology and test platforms used for molecular testing of Mycobacterium tuberculosis as a basis for understanding how mutations are associated with drug resistance...
This pocket card provides information on the treatment of drug-susceptible TB disease. The pocket card is adapted from the 2016 Official American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America Clinical Practice Guidelines: Treatment of Drug...
This guide is intended to help health care providers use audiometry to make informed and patient-centered decisions to prevent and manage ototoxicity resulting from second-line anti-TB injectables.
This material is a collection of 45 examples of the prevention, control, and care of TB. There are examples from 21 countries, including 14 countries of high priority for MDR TB and countries with high and low TB incidence.
This document is a compilation of survivor stories that feature the personal journeys of 15 individuals who have fought against TB disease.
This fact sheet provides information on the connection between TB and diabetes and outlines activities where TB and diabetes programs can collaborate.
This document highlights how the Ministries of Health of the 30 highest TB burden countries, and their partners, are beginning to adopt, adapt and implement the End TB Strategy.
This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.
